Clinical Trials Directory

Trials / Terminated

TerminatedNCT01036724

Guided Radiofrequency Ablation Using the CARTO® 3 and NavX™ Systems for the Treatment of Paroxysmal Atrial Fibrillation

Comparative Study of Guided Radiofrequency Ablation Using the CARTO® 3 and NavX™ Systems for the Treatment of Paroxysmal Atrial Fibrillation

Status
Terminated
Phase
Study type
Observational
Enrollment
107 (actual)
Sponsor
Biosense Webster, Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine the change in median radiation exposure time and median procedure time following guided radiofrequency (RF) ablation among subjects undergoing treatment for paroxysmal atrial fibrillation with either the CARTO® 3 or the NavX(TM) System. It is hypothesized that described features will reduce the median radiation exposure during the CARTO® 3 system-guided procedures compared to the NavX(TM) system-guided procedures.

Conditions

Interventions

TypeNameDescription
DEVICECardiac MappingGenerating a cardiac map using the study device (CARTO 3) compared to the control device (NAVX\[TM\]) and measuring the amount of radiation exposure duration for each.

Timeline

Start date
2009-11-01
Primary completion
2010-08-01
Completion
2010-08-25
First posted
2009-12-21
Last updated
2017-09-27
Results posted
2014-07-21

Locations

6 sites across 1 country: Canada

Source: ClinicalTrials.gov record NCT01036724. Inclusion in this directory is not an endorsement.

Guided Radiofrequency Ablation Using the CARTO® 3 and NavX™ Systems for the Treatment of Paroxysmal Atrial Fibrillation (NCT01036724) · Clinical Trials Directory